Eisai establishes Singapore clinical research base
To oversee drug studies in the Asia-Oceania region
Japanese company Eisai Co has established a clinical research base in Singapore to oversee drug studies in the Asia-Oceania region.
The company currently spends about 10% of its total ¥50bn (Euro 321m) clinical research budget in that region.
Eisai sees this as a springboard to greater business in China and India. "By establishing a base of operations in Singapore, the company can boost the speed and efficiency of clinical drug development and build a foundation on which to expand clinical studies in the area," the company said.
Many leading Western drug companies have bases in Singapore, but Eisai is the first Japanese drug maker to do so. Starting with a staff of six and expanding next year to around 10, the new base will manage the clinical drug studies being conducted on behalf of Eisai in the region, taking over the task from Eisai's existing clinical research base in the UK.
The first group of studies includes clinical development of drugs for Alzheimer's disease, Parkinson's disease and breast cancer.